Pentazyme for treating and improving diarrhea, constipation and irritable bowel syndrome

Abstract

The present invention discloses a five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome. The five-joint bacteria include Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2. The strain was discovered by the team of Professor Lin Junfang of South China Agricultural University. The probiotic composition of the present invention cooperates with each other and synergizes to effectively restore the balance of intestinal flora structure by increasing the propulsion rate of the small intestine, reducing the number of diarrhea, etc. Whether it is a live bacteria or an inactivated state, it has a good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The five-joint composite probiotics are highly safe, will not cause adverse reactions such as electrolyte imbalance, and can be used to prepare medicines or health foods or foods.

Description

Technical Field

[0001] The present invention relates to the field of probiotics and microecological preparations, and in particular to a Pentabiotics bacteria capable of regulating and improving diarrhea, constipation and irritable bowel syndrome and an application thereof. Background Art

[0002] The intestinal microbiota plays a vital role in maintaining health. They are involved in multiple physiological processes from nutrient absorption to immune regulation. However, this microbial balance may be disrupted by a variety of factors such as diet, lifestyle, antibiotic use, and disease, leading to intestinal flora imbalance. This imbalance is associated with gastrointestinal diseases such as diarrhea, constipation, and irritable bowel syndrome (IBS).

[0003] Diarrhea and constipation are common symptoms of intestinal dysfunction, and IBS is a common functional bowel disease characterized by chronic abdominal pain, discomfort, bloating, and changes in bowel habits. Abdominal pain often eases after defecation, which significantly reduces the patient's quality of life and work efficiency. The exact cause of IBS is not yet fully understood, and there is still a lack of very effective treatment for IBS, but studies have shown that changes in intestinal flora play an important role in its development. In the intestinal flora of IBS patients, the ratio of Firmicutes to Bacteroidetes increases, the diversity of the flora decreases, and the number of mucosa-associated flora increases and the composition changes. IBS can be divided into four subtypes: constipation, diarrhea, mixed, and amorphous. The diarrhea type is the most common subtype. In the treatment of IBS, the effect of probiotics has been supported by some clinical studies.

[0004] Probiotics colonize in the host's intestines or reproductive system, can improve intestinal health, balance the flora, and are called microecological regulators. Their probiotic effects are mainly achieved by improving the balance of the host flora and activating the activity of the host's endogenous microbial flora or immune system, which has a beneficial effect on the body. As beneficial active microorganisms, probiotics have been widely studied for restoring the balance of intestinal flora. They play a role by enhancing the barrier function of the intestinal mucosa, preventing the adhesion and colonization of pathogens, and enhancing immune response. Probiotics have a variety of physiological functions, mainly including helping the absorption of nutrients, regulating intestinal flora, improving diarrhea, relieving allergic reaction symptoms, improving the body's immunity, and reducing the risk of infection with inflammatory bowel disease, irritable bowel syndrome and other diseases. However, there are few studies on the use of multiple strains of probiotics to synergistically enhance the effect of compound compositions in improving diarrhea, constipation, and irritable bowel syndrome. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a five-joint bacteria and application thereof that can improve diarrhea, constipation and irritable bowel syndrome, wherein the five-joint bacteria is composed of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the preservation number of the Lactobacillus reuteri HBM11-69 is GDMCC NO: 63608, the preservation number of the Pediococcus pentosaceus MPL5 is GDMCC NO: 63606, the preservation number of the Lactobacillus plantarum La-10 is GDMCC NO: 63605, the preservation number of the Lactobacillus rhamnosus HBM11-35 is GDMCC NO: 63607, and the preservation number of the Lactobacillus casei C7-2 is GDMCC NO: 63609.

[0006] Preferably, the viable count ratio of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2 is 2:(1-10):(1-10):(1-10):(1-10). Further preferably, the viable count ratio is 2:(1-5):(1-5):(1-5):(1-5), and more preferably the viable count ratio is 2:3:2:1:2, 2:2:1:3:3, 2:1:1:1:1, 2:3:5:2:1, 2:2:3:5:5.

[0007] The present invention also provides the use of Pentazyme for regulating and improving diarrhea, constipation and irritable bowel syndrome in the preparation of products for improving diarrhea, constipation and irritable bowel syndrome.

[0008] Preferably, the product is an oral preparation.

[0009] Preferably, the oral preparation is in the form of oral liquid, drops, tablets, powders, capsules or granules.

[0010] Further preferably, the Pentabiotica for treating and improving diarrhea, constipation and irritable bowel syndrome is used in the preparation of medicines for treating and improving diarrhea, constipation and irritable bowel syndrome.

[0011] More preferably, the Pentabiotica is used in the preparation of a medicine for improving diarrhea and constipation.

[0012] Further preferably, the Pentazyme is used in the preparation of a medicament for improving or regulating irritable bowel syndrome.

[0013] The present invention also provides a composite probiotic for improving or regulating diarrhea, constipation and irritable bowel syndrome. The composite probiotic comprises five bacteria, and the five bacteria consist of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609.

[0014] Preferably, the viable count ratio of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2 in the five bacteria is 2:(1-10):(1-10):(1-10):(1-10). Further preferably, the viable count ratio is 2:(1-5):(1-5):(1-5):(1-5), and more preferably the viable count ratio is 2:3:2:1:2, 2:2:1:3:3, 2:1:1:1:1, 2:3:5:2:1, 2:2:3:5:5.

[0015] It is further preferred that the composite probiotic agent further comprises a protective agent and / or a prebiotic and / or a medicine-food homologous substance. The protective agent and / or a prebiotic and / or a medicine-food homologous substance may be selected from conventional probiotic protective agents and / or prebiotics and / or medicine-food homologous substances. The protective agent includes but is not limited to any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, sucrose, lactose, trehalose, sorbitol or xylitol; prebiotics include but are not limited to any one or a combination of at least two of oligofructose, galacto-oligosaccharide, oligoxylose, oligomalto-oligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, versicolor polysaccharide, stachyose, polydextrose, α-lactalbumin or lactoferrin; medicine-food homologous substances include but are not limited to any one or a combination of at least two of hawthorn, yam, wolfberry, Poria, Alpinia oxyphylla, Polygonatum sibiricum, Pueraria root, Angelica sinensis, Curcuma longa, Codonopsis pilosula.

[0016] In the present invention, the selected probiotic strain can be cultured (including but not limited to single fermentation and / or symbiotic fermentation) according to any suitable method known in the art, and the selected probiotic powder can be prepared by, for example, freeze drying or spray drying. For example, after the probiotics of the present invention are activated, cultured in a culture medium with seed liquid, prepared in a seed tank and fermented, the bacteria are collected by centrifugation, and a freeze-drying protective agent is added to freeze-dry the bacteria to obtain the bacterial powder.

[0017] Preferably, the composite probiotic further comprises acceptable excipients.

[0018] More preferably, the acceptable excipients may be selected from one or more of diluents, excipients, binders, lubricants, suspending agents, coating agents and solubilizers.

[0019] Preferably, the composite probiotic is a medicine, and its dosage form is oral liquid, drops, tablets, powder, capsules or granules.

[0020] Preferably, the number of viable bacteria in the composite probiotic is greater than 1×10 9 CFU / g or 1×10 9 CFU / ml.

[0021] The five strains of probiotics described in the present invention were discovered by Professor Lin Junfang's team from South China Agricultural University and later transferred to Jianma Pharmaceutical Co., Ltd. The plant lactobacillus La-10 is classified and named Lactiplantibacillus plantarum, and is deposited in the Guangdong Provincial Microbial Culture Collection Center with a deposit number of GDMCC No: 63605. The deposit time is June 30, 2023. The deposit unit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences; Pediococcus pentosaceus MPL5 is classified and named Pediococcus pentosaceus, and is deposited in the Guangdong Provincial Microbial Culture Collection Center with a deposit number of GDMCC No: 63606. The deposit time is June 30, 2023. The deposit unit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences; Lactobacillus rhamnosus HBM11-35 is classified and named Lacticaseibacillus rhamnosus, and is deposited in the Guangdong Provincial Microbial Culture Collection Center with a deposit number of GDMCC No.:63607, the preservation date is June 30, 2023, and the preservation unit address is the 5th floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences; Lactobacillus reuteri HBM11-69, classified as Limosilactobacillus reuteri, is preserved in Guangdong Microbiological Culture Collection Center, with the preservation number GDMCCNo:63608, the preservation date is June 30, 2023, and the preservation unit address is the 5th floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences; Lactobacillus casei C7-2, classified as Lacticaseibacillus casei, is preserved in Guangdong Microbiological Culture Collection Center, with the preservation number GDMCC No:63609, the preservation date is June 30, 2023, and the preservation unit address is the 5th floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences.

[0022] The probiotics of the present invention have been subjected to toxic and side effect experiments, and the results show that the probiotics have no significant effect on the experimental mice, no significant changes in body weight, no death, and no obvious pathological symptoms, and are natural and safe composite bacteria. Preliminary experiments have proved that the pentabiotics have good tolerance to artificial gastrointestinal fluid.

[0023] The beneficial technical effect of the present invention is that the composite five-joint bacteria composed of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2 described in the present invention is a microecological preparation that can be bidirectionally regulated and can effectively improve diarrhea, constipation, and irritable bowel syndrome, and the improvement effect is significantly better than the effect of using it alone or in combination with some of the probiotics. The composite five-joint bacteria can cooperate with each other to supplement the deficiencies in the efficacy of the different strains, can effectively restore the balance of the intestinal flora structure, and achieve a good synergistic effect. Whether it is a live bacteria or an inactivated state, it has a good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The five-joint bacteria are highly safe and can be used to prepare oral preparations, and have a very wide range of application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is the effect of each group on the small intestinal motility function of constipated mice.

[0025] Figure 2 This is a comparison of the antidiarrheal effects of each group on diarrhea-type IBS in mice induced by senna leaves.

[0026] Note: Compared with the model control group, * P<0.05, ** P<0.01. DETAILED DESCRIPTION

[0027] The present invention is described clearly and completely below in conjunction with specific embodiments, but the present invention is not limited thereto. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. Example 1

[0028] A five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome, characterized in that the five-joint bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609. The live cell count ratio of the Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:3:2:1:2. Example 2

[0029] A five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome, characterized in that the five-joint bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609. The live cell count ratio of the Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:2:1:3:3. Example 3

[0030] A five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome, characterized in that the five-joint bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609. The live cell count ratio of the Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:1:1:1:1. Example 4

[0031] A five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome, characterized in that the five-joint bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609. The live cell count ratio of the Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:3:5:2:1. Example 5

[0032] A five-joint bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome, characterized in that the five-joint bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, and the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609.

[0033] The live cell count ratio of the Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:2:3:5:5. Comparative Example 1

[0034] A composite bacteria, characterized in that the composite bacteria consists of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10 and Lactobacillus rhamnosus HBM11-35; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, and the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607.

[0035] The live cell count ratio of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10 and Lactobacillus rhamnosus HBM11-35 is 2:3:2:1. Comparative Example 2

[0036] A composite bacteria, characterized in that the composite bacteria consists of Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2; the preservation number of the Lactobacillus plantarum La-10 is GDMCC NO: 63605, the preservation number of the Lactobacillus rhamnosus HBM11-35 is GDMCC NO: 63607, and the preservation number of the Lactobacillus casei C7-2 is GDMCC NO: 63609.

[0037] The live cell count ratio of Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35 and Lactobacillus casei C7-2 is 2:1:2. Comparative Example 3

[0038] A probiotic, characterized in that the probiotic consists of Lactobacillus plantarum La-10; the preservation number of the Lactobacillus plantarum La-10 is GDMCC NO: 63605.

[0039] Experimental Example 1 Investigation of the effect of the probiotics of the present invention on constipation model mice

[0040] The probiotics described in the present invention are provided by Jianma Pharmaceutical (Guangdong) Co., Ltd., and other raw materials and reagents can be obtained commercially. The method for preparing the bacterial suspension involved in the experiment is as follows: the probiotics are inoculated into the MRS liquid culture medium, cultured at 34-39°C for 18h-24h for activation, and activated twice in succession to obtain an activated liquid; the activated liquid is inoculated into the MRS liquid culture medium at an inoculation rate of 2%-4% (v / v), and cultured at 34-39°C for 18h-24h to obtain a bacterial liquid; the bacterial liquid is centrifuged, the bacteria are resuspended with PBS, and the required concentration of the bacterial liquid is adjusted according to the experiment.

[0041] 120 SPF male Kunming mice weighing 18-23g were selected. The mice were adaptively cultured for one week and the animals were free to eat and drink. The experimental animals were randomly divided into 10 groups, with 12 mice in each group, namely blank group, model control group, Example 1-5 group, and comparative example 1-3 group. Except for the blank group, each group was gavaged with loperamide hydrochloride every day, once in the morning and once in the evening, for 7 consecutive days to induce a functional constipation model in mice, and the blank group was gavaged with the same amount of normal saline. Then, 0.2mL of bacterial solution was gavaged every day from the example and the comparative example, and the concentration of the bacterial solution was 1.0×10 9 CFU / mL. The blank group and the model control group were gavaged with an equal volume of saline. All mice were free to drink water and eat, and the feeding was continued for 14 days. After 14 days, the mice in each group were fasted for 12 hours but not water, and then each group was gavaged for the last time. One hour after the gavage, an equal amount of activated carbon suspension was given. After 20 minutes, the mice were killed by dislocation, the abdomen was opened to obtain the small intestine, the carbon powder advancement distance and the total length of the small intestine were measured, and the advancement rate (%) was calculated. The test results are shown in Table 1.

[0042] Propulsion rate (%) = activated carbon propulsion length (cm) / total length of small intestine (cm) × 100%

[0043] Table 1 Effects on small intestinal motility of constipated mice (MEAN±SD, n=12)

[0044]

[0045] As can be seen from Table 1, the small intestinal propulsion rate of the model control group is significantly lower than that of the blank group, indicating that the constipation model is successful. At the same time, the small intestinal propulsion rate of the composite pentabiotic group (example group) prepared by the present invention is significantly higher than that of the comparative group and the model control group, indicating that it can effectively promote gastrointestinal motility. The pentabiotic group of the specific bacteria species works together to exert synergistic synergy, accelerates the propulsion speed of activated carbon in the small intestine, and thus can improve and treat constipation.

[0046] Experimental Example 2 Effect of the probiotics of the present invention on diarrhea-type IBS in mice induced by senna leaves

[0047] 120 SPF male Kunming mice weighing 18-23g were selected. The mice were adaptively cultured for one week and the animals were free to eat and drink. The experimental animals were randomly divided into 10 groups, 12 in each group, namely, blank group, model control group, Example 1-5 group, and Comparative Example 1-3 group. Each group was pre-administered with liquid for 6 days, and the Example and Comparative Example were gavaged with 0.2mL of the corresponding bacterial solution every day, and the concentration of the bacterial solution was 1.0×10 9 CFU / mL (see the above test example for the preparation of bacterial solution), the blank group and the model control group were gavaged with the same amount of normal saline once a day. Fasting for 12 hours before the last administration of solution, 1 hour after the administration, the mice except the blank group were gavaged with senna leaf decoction at a dose of 1g crude drug / kg to establish a diarrhea-type irritable bowel syndrome model, and the blank group was given the same volume of deionized water. The diarrhea of ​​mice was counted from 3 hours after gavage, and the number of diarrhea times in the two time periods of 3 hours and 6 hours was calculated to compare the statistical differences between the groups. Soft stools, watery stools, mucous stools, etc. are called diarrhea stools. The test results are shown in Table 2.

[0048] Table 2 Comparison of antidiarrheal effects on diarrhea-type IBS in mice induced by senna leaves (MEAN±SD, n=12)

[0049]

[0050] From the experimental results in Table 2, it can be seen that intragastric administration of senna leaf decoction can effectively prepare a mouse diarrhea model. Compared with the model group, the number of diarrhea episodes in each group given different test substances decreased. Under the same probiotic dosage, the composite probiotic combination containing five species can better improve the incidence of diarrhea, while the effect of using them alone or in combination with some of the probiotics did not significantly improve the related diarrhea frequency. It can be seen that the pentabiotics described in the present application can better promote the proliferation and colonization of probiotics in the body, improve the intestinal environment, have a significant inhibitory effect on diarrhea-type IBS, and can effectively relieve diarrhea symptoms.

[0051] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions (including but not limited to changes in strain numbers), changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.

Claims

1. An application of Pentazyme for conditioning and improving diarrhea, constipation and irritable bowel syndrome in the preparation of an oral preparation for improving diarrhea, constipation and irritable bowel syndrome, characterized in that: The five-joint bacteria are composed of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2; the Lactobacillus reuteri HBM11-69 has a preservation number of GDMCC NO: 63608, the Pediococcus pentosaceus MPL5 has a preservation number of GDMCC NO: 63606, the Lactobacillus plantarum La-10 has a preservation number of GDMCC NO: 63605, the Lactobacillus rhamnosus HBM11-35 has a preservation number of GDMCC NO: 63607, the Lactobacillus casei C7-2 has a preservation number of GDMCC NO: 63609, the NO: 63609, the ratio of the viable cell count of Lactobacillus reuteri HBM11-69, Pediococcus pentosaceus MPL5, Lactobacillus plantarum La-10, Lactobacillus rhamnosus HBM11-35, and Lactobacillus casei C7-2 is 2:(1-5):(1-5):(1-5):(1-5).

2. The use according to claim 1, characterized in that: The oral preparation is in the form of oral liquid, drops, tablets, powders, capsules or granules.

Images